Trial Profile
Randomized, Double-Masked, Placebo-controlled Evaluation of the Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis Who Undergo Tapering of Concomitant Immunosuppressive Medications
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Apr 2014
Price :
$35
*
At a glance
- Drugs Basiliximab (Primary)
- Indications Uveitis
- Focus Therapeutic Use
- Sponsors Cerimon Pharmaceuticals
- 19 Apr 2014 New trial record